{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:33:40Z","timestamp":1792290820966,"version":"4.4.0"},"reference-count":45,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Peritoneal carcinomatosis is an advanced stage of cancer in which the disease has spread to the peritoneal cavity. In order to restore antitumor immunity subverted by tumor cells in this location, we evaluated intraperitoneal administrations of modified vaccinia virus Ankara (MVA) engineered to express single-chain interleukin 12 (scIL-12) to increase antitumor immune responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MVA encoding scIL-12 (MVA.scIL-12) was evaluated against peritoneal carcinomatosis models based on intraperitoneal engraftment of tumor cells. CD8-mediated immune responses, elucidated antitumor efficacy, and safety were evaluated following intravenous, intratumoral, or intraperitoneal administration of the viral vector. The immune response was measured by ELISpot (enzyme-linked immunosorbent spot), RNA sequencing, flow cytometry, intravital microscopy, and depletion of lymphocyte subsets with monoclonal antibodies. Safety was assessed by body-weight follow-up and blood testing. Tissue tropism on intravenous or intraperitoneal administration was assessed by bioluminescence analysis using a reporter MVA encoding luciferase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Intraperitoneal or locoregional administration, but not other routes of administration, resulted in a potent immune response characterized by increased levels of tumor-specific CD8<jats:sup>+<\/jats:sup> T lymphocytes with the ability to produce both interferon-\u03b3 and tumor necrosis factor-\u03b1. The antitumor immune response was detectable not only in the peritoneal cavity but also systemically. As a result of intraperitoneal treatment, a single administration of MVA.scIL-12 encoding scIL-12 completely eradicated MC38 tumors implanted in the peritoneal cavity and also protected cured mice from subsequent subcutaneous rechallenges. Bioluminescence imaging using an MVA encoding luciferase revealed that intraperitoneal administration targets transgene to the omentum. The omentum is considered a key tissue in immune protection of the peritoneal cavity. The safety profile of intraperitoneal administration was also better than that following intravenous administration since no weight loss or hematological toxicity was observed when the vector was locally delivered into the peritoneal cavity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Intraperitoneal administration of MVA vectors encoding scIL-12 targets the omentum, which is the tissue where peritoneal carcinomatosis usually begins. MVA.scIL-12 induces a potent tumor-specific immune response that often leads to the eradication of experimental tumors disseminated to the peritoneal cavity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-006702","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:30:12Z","timestamp":1698931812000},"page":"e006702","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis"],"prefix":"10.1136","volume":"11","author":[{"given":"\u00c1ngela","family":"Bella","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Arrizabalaga","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Augusta","family":"Di Trani","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gonzalez-Gomariz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gomar","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Salvador","family":"Russo-Cabrera","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Olivera","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Cirella","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Fernandez-Sendin","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-4464","authenticated-orcid":false,"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Atay","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Medina-Echeverz","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-9134","authenticated-orcid":false,"given":"Maria","family":"Hinterberger","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Hochrein","sequence":"additional","affiliation":[{"name":"Bavarian Nordic GmbH, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"},{"name":"Department of Oncology and Department of Immunology and Immunotherapy, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Nuffield Department of Medicine and Oxford Center for Immuno-Oncology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":false,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9364-474X","authenticated-orcid":false,"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"2025100309392024000_11.11.e006702.1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i41.6979"},{"key":"2025100309392024000_11.11.e006702.2","first-page":"441","article-title":"Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment","volume":"23","author":"Cavaliere","year":"2009","journal-title":"In Vivo"},{"key":"2025100309392024000_11.11.e006702.3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","article-title":"Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review","volume":"66","author":"van Baal","year":"2018","journal-title":"J Histochem Cytochem"},{"key":"2025100309392024000_11.11.e006702.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650098","article-title":"Peritoneal metastases from colorectal cancer: defining and addressing the challenges","volume":"11","author":"Kranenburg","year":"2021","journal-title":"Front Oncol"},{"key":"2025100309392024000_11.11.e006702.5","doi-asserted-by":"crossref","first-page":"14371","DOI":"10.3748\/wjg.v20.i39.14371","article-title":"Peritoneal carcinomatosis of gastrointestinal tumors: where are we now","volume":"20","author":"Terzi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025100309392024000_11.11.e006702.6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v6.i2.169"},{"key":"2025100309392024000_11.11.e006702.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.014"},{"key":"2025100309392024000_11.11.e006702.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.03.002"},{"key":"2025100309392024000_11.11.e006702.9","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MIR0720-271RR"},{"key":"2025100309392024000_11.11.e006702.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.04.005"},{"key":"2025100309392024000_11.11.e006702.11","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01246-z","article-title":"Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the Omentum via CCR1","volume":"3","author":"Krishnan","year":"2020","journal-title":"Commun Biol"},{"key":"2025100309392024000_11.11.e006702.12","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191869","article-title":"Tissue-resident macrophages in Omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J Exp Med"},{"key":"2025100309392024000_11.11.e006702.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181170"},{"key":"2025100309392024000_11.11.e006702.14","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025100309392024000_11.11.e006702.15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.suronc.2015.11.003","article-title":"Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission and morbidity prognostic score","volume":"25","author":"Malfroy","year":"2016","journal-title":"Surg Oncol"},{"key":"2025100309392024000_11.11.e006702.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-019-1618-4","article-title":"Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using Oxaliplatin: a retrospective single-arm cohort study","volume":"17","author":"Burnett","year":"2019","journal-title":"World J Surg Oncol"},{"key":"2025100309392024000_11.11.e006702.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"2025100309392024000_11.11.e006702.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(Ecto) directed Chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"2025100309392024000_11.11.e006702.19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2016.49","article-title":"Intraperitoneal immunotherapy: historical perspectives and modern therapy","volume":"23","author":"Morano","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"2025100309392024000_11.11.e006702.20","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz027.002","article-title":"4P - Novel applications of MVA to improve outcomes in Immunooncology","volume":"30","author":"Heery","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100309392024000_11.11.e006702.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0743"},{"key":"2025100309392024000_11.11.e006702.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003989","article-title":"Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS\/STING-mediated cytosolic DNA-sensing pathway","volume":"10","author":"Dai","year":"2014","journal-title":"PLoS Pathog"},{"key":"2025100309392024000_11.11.e006702.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001586","article-title":"Intratumoral virotherapy with 4-1BBL armed modified vaccinia ankara eradicates solid tumors and promotes protective immune memory","volume":"9","author":"Hinterberger","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100309392024000_11.11.e006702.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat Commun"},{"key":"2025100309392024000_11.11.e006702.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001587","article-title":"Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia ankara viral vectors","volume":"9","author":"Tenesaca","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100309392024000_11.11.e006702.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817307"},{"key":"2025100309392024000_11.11.e006702.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0381"},{"key":"2025100309392024000_11.11.e006702.28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438800","article-title":"Heterodimeric FC-fused Il12 shows potent antitumor activity by generating memory CD8(+) T cells","volume":"7","author":"Jung","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100309392024000_11.11.e006702.29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/jir.2018.0129","article-title":"Development of an Interleukin-12 fusion protein that is activated by cleavage with matrix metalloproteinase 9","volume":"39","author":"Skrombolas","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"2025100309392024000_11.11.e006702.30","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci Immunol"},{"key":"2025100309392024000_11.11.e006702.31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"2025100309392024000_11.11.e006702.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0472"},{"key":"2025100309392024000_11.11.e006702.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat Commun"},{"key":"2025100309392024000_11.11.e006702.34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100309392024000_11.11.e006702.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108189"},{"key":"2025100309392024000_11.11.e006702.36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"2025100309392024000_11.11.e006702.37","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1923"},{"key":"2025100309392024000_11.11.e006702.38","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616"},{"key":"2025100309392024000_11.11.e006702.39","doi-asserted-by":"crossref","unstructured":"Korotkevich G , Sukhov V , Budin N , et al . Fast gene set enrichment analysis. Bioinformatics [Preprint]. doi:10.1101\/060012","DOI":"10.1101\/060012"},{"key":"2025100309392024000_11.11.e006702.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0244"},{"key":"2025100309392024000_11.11.e006702.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100309392024000_11.11.e006702.42","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100309392024000_11.11.e006702.43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s13193-022-01592-w","article-title":"Peritoneal metastases from extraperitoneal primary tumors: incidence, treatment, and survival from a nationwide database","volume":"14","author":"Rijken","year":"2023","journal-title":"Indian J Surg Oncol"},{"key":"2025100309392024000_11.11.e006702.44","doi-asserted-by":"crossref","first-page":"631609","DOI":"10.3389\/fimmu.2021.631609","article-title":"The essential involvement of the Omentum in the peritoneal defensive mechanisms during intra-abdominal sepsis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"2025100309392024000_11.11.e006702.45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/sciimmunol.abq7432","article-title":"CDC1 coordinate innate and adaptive responses in the Omentum required for T cell priming and memory","volume":"7","author":"Christian","year":"2022","journal-title":"Sci Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:39:33Z","timestamp":1759509573000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/jitc-2023-006702"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006702","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}